摘要
目的探究食管癌根治术联合新辅助化疗治疗食管癌的临床疗效及对预后的影响。方法选取2018年1月至2019年2月赣州市人民医院收治的80例食管癌患者作为研究对象,按抽签顺序分为对照组和观察组,每组40例。对照组行食管癌根治术,观察组在对照组基础上联合新辅助化疗。比较两组治疗前后血管新生指标[内皮生长因子(VEGF)、转化生长因子-β_(1)(TGF-β_(1))、基质金属蛋白酶9(MMP-9)]、1年生存率及复发率。结果治疗前,两组VEGF、TGF-β_(1)、MMP-9比较差异无统计学意义;治疗后,两组VEGF、TGF-β_(1)、MMP9水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。随访1年后,观察组生存率高于对照组,复发率低于对照组,差异有统计学意义(P<0.05)。结论食管癌根治术联合新辅助化疗治疗食管癌患者疗效显著,可有效抑制肿瘤血管新生,提高1年后生存率,降低复发率,值得临床推广应用。
Objective To investigate the clinical efficacy and prognosis of esophageal cancer treated by radical resection combined with neoadjuvant chemotherapy.Methods 80 patients with esophageal cancer admitted to Ganzhou People's Hospital from January 2018 to February 2019 were selected as research subjects and they were divided into control group and observation group according to the order of lot,with 40 cases in each group.The control group was treated with radical resection of esophageal cancer,and the observation group was combined with neoadjuvant chemotherapy on the basis of control group.The angiogenesis index(vascular endothelial growth factor[VEGF],transforming growth factor-β_(1)[TGF-β_(1)],matrix metalloproteinase 9[MMP-9]),1-year survival rate and recurrence rate before and after treatment were compared between the two groups.Results Before treatment,there was no significant difference in VEGF,TGF-β_(1) and MMP-9 between the two groups;after treatment,the levels of VEGF,TGF-β_(1) and MMP-9 in the two groups were lower than before treatment,and the observation group was lower than control group,the difference was statistically significant(P<0.05).After 1 year of follow-up,the survival rate of observation group was higher than control group,and the recurrence rate was lower than control group,the difference was statistically significant(P<0.05).Conclusion Radical resection of esophageal cancer combined with neoadjuvant chemotherapy has significant effect on patients with esophageal cancer,which can effectively inhibit tumor angiogenesis,improve the survival rate after 1 year,and reduce the recurrence rate,which is worthy of clinical application.
作者
蓝素珍
黄子葵
LAN Suzhen;HUANG Zikui(Department of Oncology,Ganzhou People's Hospital,Ganzhou,Jiangxi,341400,China;Department of Traditional Chinese Medicine,Ganzhou People's Hospital,Ganzhou,Jiangxi,341400,China)
出处
《当代医学》
2022年第34期148-150,共3页
Contemporary Medicine
基金
江西省赣州市指导性科技计划项目(GZ2018ZSF302)。
关键词
食管癌
根治术
新辅助化疗
生存率
Esophageal cancer
Radical resection
Neoadjuvant chemotherapy
Survival rate
